Skip to main content
. Author manuscript; available in PMC: 2011 May 17.
Published in final edited form as: Surgery. 1986 Oct;100(4):705–715.

Fig. 6.

Fig. 6

A, The actuarial survival rate for 382 grafts for which both antibody crossmatch and PRA data are available is compared with survival rate for the entire series of 667 transplants. There is no significant difference. B, The actuarial survival rate for 282 grafts in patients with a positive crossmatch and a PRA greater than 30% (including 20 patients with a PRA more than 60%) is compared with survival rate for 305 grafts in patients with a negative crossmatch and PRA less than 30%. There are no significant differences in graft survival rates.